Literature DB >> 21847635

A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study.

Leena Choi1, Brian S Caffo, Utkarsh Kohli, Pratik Pandharipande, Daniel Kurnik, E Wesley Ely, C Michael Stein.   

Abstract

The purpose of this study is to develop a statistical methodology to handle a large proportion of artifactual outliers in a population pharmacokinetic (PK) modeling. The motivating PK data were obtained from a population PK study to examine associations between PK parameters such as clearance of dexmedetomidine (DEX) and cytochrome P450 2A6 phenotypes. The blood samples were sparsely sampled from patients in intensive care units (ICUs) while different doses of DEX were continuously infused. Conventional population PK analysis of these data revealed several challenges and intricacies. Especially, there was strong evidence that some plasma drug concentrations were artifactually high and likely contaminated with the infused drug due to blood sampling processes that are sometimes unavoidable in an ICU setting. If not addressed, or if arbitrarily excluded, these outlying values could lead to biased estimates of PK parameters and miss important relationships between PK parameters and covariates due to increased variability. We propose a novel population PK model, a Bayesian hierarchical nonlinear mixture model, to accommodate the artifactual outliers using a finite mixture as the residual error model. Our results showed that the proposed model handles the outliers well. We also conducted simulation studies with a varying proportion of the outliers. These simulation results showed that the proposed model can accommodate the outliers well so that the estimated PK parameters are less biased.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847635      PMCID: PMC3182101          DOI: 10.1007/s10928-011-9211-7

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  18 in total

1.  Generalized nonlinear models for pharmacokinetic data.

Authors:  J K Lindsey; W D Byrom; J Wang; P Jarvis; B Jones
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

2.  Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret.

Authors:  R M Venn; M D Karol; R M Grounds
Journal:  Br J Anaesth       Date:  2002-05       Impact factor: 9.166

3.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

4.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

5.  The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.

Authors:  Hanna E Silber; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-14       Impact factor: 2.745

6.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.

Authors:  A Mallet; F Mentré; J L Steimer; F Lokiec
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

7.  A bayesian approach to some outlier problems.

Authors:  G E Box; G C Tiao
Journal:  Biometrika       Date:  1968-03       Impact factor: 2.445

Review 8.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

9.  The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers.

Authors:  J B Dyck; M Maze; C Haack; L Vuorilehto; S L Shafer
Journal:  Anesthesiology       Date:  1993-05       Impact factor: 7.892

10.  Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.

Authors:  Utkarsh Kohli; Mordechai Muszkat; Gbenga G Sofowora; Paul A Harris; Eitan A Friedman; William D Dupont; Mika Scheinin; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Eur J Pain       Date:  2009-05-06       Impact factor: 3.931

View more
  6 in total

1.  CYP2A6 genetic variation and dexmedetomidine disposition.

Authors:  Utkarsh Kohli; Pratik Pandharipande; Mordechai Muszkat; Gbenga G Sofowora; Eitan A Friedman; Mika Scheinin; Alastair J J Wood; E Wesley Ely; Rachel F Tyndale; Leena Choi; C Michael Stein; Daniel Kurnik
Journal:  Eur J Clin Pharmacol       Date:  2012-01-21       Impact factor: 2.953

2.  Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Kana Mizuno; Min Dong; Tsuyoshi Fukuda; Sharat Chandra; Parinda A Mehta; Scott McConnell; Elias J Anaissie; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

3.  Population Pharmacokinetics of Fentanyl in the Critically Ill.

Authors:  Leena Choi; Benjamin A Ferrell; Eduard E Vasilevskis; Pratik P Pandharipande; Rebecca Heltsley; E Wesley Ely; C Michael Stein; Timothy D Girard
Journal:  Crit Care Med       Date:  2016-01       Impact factor: 7.598

4.  Population pharmacokinetics of dexmedetomidine in critically ill patients.

Authors:  Pyry Antti Välitalo; Tuula Ahtola-Sätilä; Andrew Wighton; Toni Sarapohja; Pasi Pohjanjousi; Chris Garratt
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

Review 5.  Interpatient variability in dexmedetomidine response: a survey of the literature.

Authors:  Samantha F Holliday; Sandra L Kane-Gill; Philip E Empey; Mitchell S Buckley; Pamela L Smithburger
Journal:  ScientificWorldJournal       Date:  2014-01-16

6.  The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors.

Authors:  Paweł Wiczling; Alicja Bartkowska-Śniatkowska; Oliwia Szerkus; Danuta Siluk; Jowita Rosada-Kurasińska; Justyna Warzybok; Agnieszka Borsuk; Roman Kaliszan; Edmund Grześkowiak; Agnieszka Bienert
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-05-24       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.